Your shopping cart is currently empty

KMT9-IN-1 (Compound 8) is a KMT9 inhibitor and an ethyl ester prodrug of compound 7b. Inside cells, KMT9-IN-1 releases the active form 7b through the action of esterases. It specifically associates with the KMT9 target within cells, leading to a reduction in H4K12me1 levels. KMT9-IN-1 exhibits antitumor activity against colon cancer and can be employed in research on prostate cancer and hepatocellular carcinoma.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 10 mg | Inquiry | 10-14 weeks | 10-14 weeks | |
| 50 mg | Inquiry | 10-14 weeks | 10-14 weeks |
| Description | KMT9-IN-1 (Compound 8) is a KMT9 inhibitor and an ethyl ester prodrug of compound 7b. Inside cells, KMT9-IN-1 releases the active form 7b through the action of esterases. It specifically associates with the KMT9 target within cells, leading to a reduction in H4K12me1 levels. KMT9-IN-1 exhibits antitumor activity against colon cancer and can be employed in research on prostate cancer and hepatocellular carcinoma. |
| Molecular Weight | 712.25 |
| Formula | C36H47ClFN7O5 |
| Cas No. | 2625406-61-1 |
| Smiles | O[C@H]1[C@H](N2C=3C(C=C2)=C(NC)N=CN3)C[C@H](CN(CC[C@@H](C(OCC)=O)N)CCCNCCC4=CC(F)=C(OC5=CC=C(Cl)C=C5)C=C4)[C@H]1O |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.